Progress, Potential, and Possibilities Podcast / Show

Send us a textDr. Tina Ipe, MD, MPH is Chief Executive Officer at Regen Med Clinic ( https://www.regenmed.vip/ ), a medical practice which provides multi-specialty infusions, cutting-edge treatments such as therapeutic apheresis (plasmapheresis and collections), as well as novel aesthetic treatments, for patients with a variety chronic illnesses. Dr. Ipe is a board-certified physician and clinical researcher. Before entering private practice, she was Chief Medical Officer at the Oklahoma Blood Institute, Associate Medical Director at Houston Methodist Hospital, and  Division Director at University of Arkansas for Medical Sciences (UAMS). She is an expert in the fields of blood disorders, immunology, therapeutic apheresis, blood banking, and transfusion medicine. She has published more than 50 peer-reviewed manuscripts and book chapters.Dr. Ipe received her medical degree from the Medical College of Virginia and completed her residency in clinical pathology and fellowship in transfusion medicine at the Hospital of the University of Pennsylvania. She also has an MPH from Dartmouth.#TinaIpe #BloodDisorders #Blood #Biotherapies #Immunology #TherapeuticApheresis #BloodBanking #TransfusionMedicine #RegenerativeMedicine #TherapeuticPlasmaExchange #ConvalescentPlasma #ExtracorporealPhotopheresis #Parabiosis #Longevity #Aging #HospiceCare #STEM #Innovation #Science #Technology #Research #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcastSupport the show

Send us a textDr. David B. Agus ( https://davidagus.com/ ) is one of the world's leading doctors and pioneering biomedical researchers. Dr. Agus is the Founding Director and Co-CEO of the Ellison Institute ofTechnology  ( https://eit.org/ ) and a professor of medicine ( https://keck.usc.edu/faculty-search/david-b-agus/ ) and engineering ( https://viterbi.usc.edu/directory/faculty/Agus/David ) the University ofSouthern California.A medical oncologist, Dr. Agus leads a multidisciplinary team of researchersdedicated to the development and use of technologies to guide doctors in making health-care decisions tailored to individual needs. An international leader in global health and approaches for personalized healthcare, Dr. Agus serves in leadership roles at the World Economic Forum and is co-chair of the Global Health Security Consortium ( https://institute.global/tags/global-health-security-consortium ). He is also a CBS News contributor.Dr. Agus’ three books The End of Illness, A Short Guide to a Long Life and The Lucky Years: How to Thrive in the Brave New World of Health are all New York Times and international bestsellers. His latest book, The Book of AnimalSecrets: Nature’s Lessons for a Long and Happy Life, was released in December 2023. He is a 2017 recipient of the Ellis Island Medal of Honor.#DavidAgus #LawrenceEllison #LarryEllison #TonyBlair #ShinyaYamanaka #ArtificialIntelligence #Health #MedicalScience #FoodSecurity #SustainableAgriculture #ClimateChange #CleanEnergy #DrugDiscovery #MolecularAnalytics #Microenvironment #Cancer #Oncology  #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us a textDr. Tristan Colonius, DVM is the Chief Veterinary Officer and Deputy Director for Science Policy at FDA’s Center for Veterinary Medicine ( CVM - https://www.fda.gov/animal-veterinary ). Dr. Colonius previously worked in various positions at FDA, including as Deputy Chief of Staff to Commissioner Dr. Robert Califf and as an International Policy Analyst. During his career at FDA, Dr. Colonius has been working on numerous initiatives including the Animal and Veterinary Innovation Agenda, One Health, Intentional Genomic Alterations in animals,  and zootechnical animal feed substances (ZAFS) among many other programs at CVM.Prior to joining FDA, Dr. Colonius held positions in the US Senate and US Department of Agriculture. Dr.  Colonius came to the Hill as an American Association for the Advancement of Science (AAAS) Science and Technology fellow in 2012 in Senator Kirsten Gillibrand’s (NY) office and worked to help pass the Agricultural Act of 2014 (the “Farm Bill”) renewal. Dr. Colonius then went to work for Senator Diane Feinstein, first as a Legislative Assistant and then as her Deputy Legislative Director. While in Senator Feinstein’s office, Dr. Colonius worked on disaster preparedness, climate resiliency, emerging public health threats, homeland security, federal science policy, and animal welfare/conservation.Dr. Colonius holds a BA in Political Science and Doctor of Veterinary Medicine from Louisiana State University, as well as a Master of Public Administration from the University of Illinois.Important Episode LinkThe Animal and Veterinary Innovation Agenda - Center for Veterinary Medicine (CVM) - FDA - https://www.fda.gov/news-events/press-announcements/fda-supports-innovation-animal-biotechnology-veterinary-products-food-animals-through-new#FoodAndDrugAdministration #FDA #CenterForVeterinaryMedicine #OneHealth #TristanColonius #AnimalWelfare #PetMedicine #ConditionalApproval #SciencePolicy #AntimicrobialResistance #Zoonotic #Zoooses #GMO #RobertCaliff #KirstenGillibrand #DianeFeinstein  #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us a textDr. Ricardo Baptista Leite, MD is a medical doctor trained in infectious diseases, with extensive experience in global health, health systems and science-based policy making. Dr. Baptista Leite served four terms as a Member of Parliament in Portugal on Health and Foreign Affairs committees, is currently a city councilor in Sintra, served as Deputy Mayor of Cascais, and as Head of Public Health at the Catholic University of Portugal. Dr. Baptista Leite is Founder and President of the UNITE Parliamentarians Network for Global Health ( https://www.unitenetwork.org/ ), a network of current and former policymakers from 110 countries committed towards the promotion of efficient and sustainable policies for improved global health systems, in alignment with the United Nations Sustainable Development Goals (SDGs).Dr. Baptista Leite is also CEO of HealthAI - The Global Agency for Responsible AI in Health ( https://www.healthai.agency/ ) in Geneva; Chair of the Board of the Harvard-Charité Global Health Policy Lab ( https://www.globalhealthpolicylab.org/about-us ) in Berlin; and Chair of the Centre for Global Health at NOVA University Information Management School ( https://www.novaims.unl.pt/en/nova-ims/labs/nova-center-for-global-health-lab/ ) where he also has teaching and research responsibilities at the department of Microbiology and Parasitology.Dr. Baptista Leite completed postgraduate studies at Johns Hopkins University, Harvard Kennedy School of Government and Harvard Medical School. Dr. Baptista Leite was a practicing physician for several years, including an internship at the World Health Organization. He was a medical volunteer during the COVID-19 pandemic in his hometown hospital in Portugal and as part of a humanitarian mission at the Lviv Regional Hospital in Ukraine after the beginning of the war.#RicardoBaptistaLeite #PublicHealth #GlobalHealth #InfectiousDiseases #Portugal #UNITEParliamentariansNetwork #HealthAI #HIV #AIDS #TB #Hepatitis #AntimicrobialResistance #HealthyAging #Wellbeing #UnitedNations #WHO #WorldHealthOrganization #ArtificialIntelligence #DigitalHealth #SustainableDevelopmentGoals  #OneHealth #HealthPolicy  #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast  #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us a textMike Kelly is President & Chief Executive Officer of NervGen Pharma Corp. ( https://nervgen.com/ ), a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair in the settings of traumatic injury and disease. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial in an initial target indication, spinal cord injury. NervGen has initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury.Mr. Kelly brings three decades of pharmaceutical experience playing instrumental roles in the creation, development and strengthening of several companies. Most recently, Mr. Kelly served as President of US Operations for Adapt Pharma, Inc. from March 2016 to June 2019, and played a key leadership role in the development and commercialization of NARCAN (naloxone HCl) Nasal Spray in the US and Canada and in the eventual sale to Emergent BioSolutions for US$735 million.Prior to his tenure at Adapt Pharma, Inc., Mr. Kelly served as the Chief Executive Officer and a Director of Covis Pharmaceuticals, Inc., where, along with its European affiliate, grew and sold the company assets for US$1.2 billion. Mr. Kelly was also a member of the founding management team of Azur Pharma Limited, a specialty pharmaceutical company, and later, following a strategic merger, served as the Senior Vice President of Sales and Marketing for Jazz Pharmaceuticals Inc. Mr. Kelly has also held various commercial and medical roles at Guilford Pharmaceuticals Inc., ViroPharma Incorporated and TAP Pharmaceuticals Inc. and has been a Director of ARS Pharmaceuticals Inc. since May 2019. Mr. Kelly holds a Bachelor of Science in business administration from The College of New Jersey and a Master of Business Administration from Rider University.#SpinalCordInjury #SCI #IschemicStroke #AmyotrophicLateralSclerosis #ALS #NervGen #Rehabilitation #RegenerativeMedicine #RegenerativeBiology #ChondroitinSulfateProteoglycans #STEM #Innovation #Science #Technology #Research #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcastSupport the show

Send us a textDr. Leonard Tender, Ph.D. is a Program Manager in the Biological Technologies Office at DARPA ( https://www.darpa.mil/staff/dr-leonard-tender ) where his research interests include developing new methods for user-defined control of biological processes, and climate and supply chain resilience.Prior to coming to DARPA, Dr. Tender was a principal investigator and led the Laboratory for Molecular Interfaces in the Center for Bio/Molecular Science and Engineering at the U.S. Naval Research Laboratory. There, among other accomplishments, he facilitated numerous international collaborations with key external stakeholders in academia, industry, and government and his highly interdisciplinary research team, comprised of electrochemists, microbiologists, and engineers, is widely recognized for its many contributions to the field of microbial electrochemistry.Dr. Tender earned a doctorate degree in analytical chemistry from the University of North Carolina, Chapel Hill; a bachelor’s degree in chemistry from the Massachusetts Institute of Technology; completed a post-doctoral fellowship in the Department of Chemistry from the University of California, Berkeley; and served as a visiting scientist in the Stanford University Department of Chemistry. Dr. Tender co-founded the International Society for Microbial Electrochemistry and Technology and is a recipient of the Arthur S. Flemming Award, which honors outstanding federal employees, by the George Washington University's Trachtenberg School of Public Policy and Public Administration.#Darpa #Biomanufacturing #QuantumBiology #QuantumComputing  #NavalResearchLaboratory #MicrobialElectrochemistry #DefenseAdvancedResearchProjectsAgency #Bioelectronics #TissueRegeneration #UnderseaEnergy #BreathableArmors #EdibleMacronutrients #Lubricants #Adhesives #TacticalFibers #PotableWater #Plastic #OrbitalManufacturing #Extremophiles #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us a textDr. Mehmood Khan, MD is the Chief Executive Officer of Hevolution Foundation ( https://www.hevolution.com/ ), a first of its kind non-profit organization that funds research through grants and provides investments in biotech to incentivize healthspan science across disciplines and borders for the benefit of all. Established by a Saudi Royal Decree, with its headquarters in Riyadh, with additional international hubs to support the expansion and execute the global mission, it's vision is to expand healthy human lifespan for the benefit of all humanity.  Hevolution Foundation aims to be positioned as a global leader, catalyst, partner, and convener, to increase the number of scientists entering the field, to increase the investable opportunities in the field of aging, and to help shape the regulatory and government environment.Dr. Khan also currently serves as the Executive Chairman of Life Biosciences Inc. where he joined the company in April 2019 as the Chief Executive Officer and Board Member. Life Biosciences was founded to advance scientific research and develop innovative new therapies to improve and extend healthy lives for everyone.Dr. Khan previously served as Vice Chairman and Chief Scientific Officer of Global Research and Development at PepsiCo, a Fortune 50 company employing upwards of 250,000 employees across 22 brands. At PepsiCo, Dr. Khan played a pivotal role in the company’s global R&D efforts to create breakthrough innovations in food, beverages, and nutrition, including the incorporation of healthier and more nutritious offerings across its portfolio. Dr. Khan also oversaw PepsiCo's global sustainability initiatives based on the belief that success in business is inextricably linked to the sustainability of the world we share. Prior to joining PepsiCo, Dr. Khan served as President of Global R&D at Takeda Pharmaceuticals, leading the global efforts of one of the largest pharmaceutical companies in the world by revenue.Before moving into industry, Dr. Khan had a distinguished medical career as a faculty member in endocrinology at the Mayo Clinic and Mayo Medical School where he served as Director of the Diabetes, Endocrine and Nutritional Trials Unit. He also spent nine years leading programs in diabetes, endocrinology, metabolism and nutrition in Minneapolis, MN.Dr. Khan is currently a member of the Board of Directors of Reckitt Benckiser.Dr. Khan has also served as a board member in Spectrum Health, CorMedix, HemoShear Therapeutics, and Indigo Agriculture.Dr. Khan earned his medical degree from the University of Liverpool Medical School, England, and completed a fellowship in clinical endocrinology and nutrition in the Department of Medicine and Food Science and Nutrition at the University of Minnesota, Minneapolis. He is a Fellow of the Royal College of Physicians in London and a Fellow of the American College of Endocrinology.#MehmoodKhan #HevolutionFoundation #Healthspan #Lifespan #IntrinsicCapacity #Resilience #Aging #Longevity #Rejuvenation #LifeBiosciences #Endocrinology #GeriatricSyndromes #Nutrition #Xprize #FoodScience #Diabetes #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us a textDr. Jay Hooper, Ph.D. is Chief, Molecular Virology Branch, at the U.S. Army Medical Research Institute of Infectious Diseases ( USAMRIID - https://usamriid.health.mil/ ) where his research is aimed at the discovery and development of medical countermeasures targeting exotic viral diseases of military importance including hemorrhagic fever caused by hantaviruses, arenaviruses, filoviruses (e.g., Ebola virus), and diseases caused by poxviruses (e.g., smallpox and monkeypox). Dr. Hooper’s discoveries include one of the world’s most potent monoclonal antibodies targeting smallpox (7D11), and the first practical lethal disease animal model for a hantavirus (Andes virus in Syrian hamsters). Dr. Hooper is an expert in DNA vaccine technology and the use of this technology to develop both active vaccines and passive (antibody-based) medical countermeasures, and is the lead scientist in an effort that has resulted in multiple hantavirus DNA vaccines moving into Phase 1 and 2 clinical trials. To expedite medical countermeasure research, Dr. Hooper’s group established a pseudovirion neutralization assay capability which has been used to support the rapid development of candidate antibody-based products and vaccines, including candidate Ebola virus vaccines. During the COVID-19 outbreak Dr. Hooper led an effort to establish rodent animal models to discover and advance medical countermeasures targeting COVID-19. That work resulted in among the first publications on the use of the Syrian hamster model, and human ACE2 mouse model, to evaluate medical countermeasures. These models were then used to advance vaccines and antibody treatments, including Operation Warp Speed-funded research. Dr. Hooper’s is currently collaborating with industrial partners to develop future generation vaccines and antibodies to combat monkeypox.Dr. Hooper has a Ph.D. in Virology from Harvard University and a BA in Biology from Colby College.#USAMRIID #MolecularVirology #MedicalCountermeasures #Hantavirus #Ebola #Monkeypox #Smallpox #Covid #MonoclonalAntibodies #Vaccines  #OperationWarpSpeed #Army #Biodefense #MrnaVaccines #DNAVaccines #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us a textDr. Oren Gilad, Ph.D., is President and Chief Executive Officer of Aprea Therapeutics ( https://aprea.com/ ), a clinical stage, platform biotechnology company focused on the development of novel, synthetic lethality-based therapies, with direct on-target mechanisms of action, and clear clinical pathways, that target various aspects of DNA Damage Response (DDR) Pathways.Dr. Gilad previously served as President and CEO of Atrin Pharmaceuticals, Inc., leading its transaction with Aprea Therapeutics. Dr. Gilad brings extensive experience across multiple phases of drug development. During his time at Atrin, he led development from idea through early stage into the clinical stage while securing financing to support pre-clinical and clinical development, regulatory, and intellectual property activities. Before founding Atrin in 2011, Dr. Gilad authored several high-impact scientific publications over a 13-year academic career, including one demonstrating the importance of the ATR kinase pathway in cancer development and treatment. Dr. Gilad earned his doctorate in comparative pathology from the University of California at Davis, did his post-doc work at University of Pennsylvania School of Medicine, and his B.S. from the Hebrew University, Jerusalem, Israel.#Cancer #Oncology #TumorBiology #OrenGilad #ApreaTherapeutics #Biotechnology #DrugDevelopment #Macrocycles #SyntheticLethality #DNADamageResponse #Doylestown #Philadelphia #ATRKinase #WEE1 #BRCA #PARP #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast  #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us a textDr. Luba Perry, Ph.D. is Co-Founder and CEO of ReConstruct Bio ( https://wyss.harvard.edu/technology/reconstruct/ ), an innovative venture emerging from Harvard’s Wyss Institute ( https://wyss.harvard.edu/team/advanced-technology-team/luba-perry/ ), aimed at redefining the fields of medical reconstruction and aesthetics with an initial application of their groundbreaking technology on breast reconstruction and augmentation. With a multidisciplinary team of experts, the ReConstruct Bio team has developed the BioImplant—a living, bioengineered tissue created from the patient’s own cells, to provide safer, more natural alternative to current standards, which are often associated with significant drawbacks and health concerns.Dr. Perry also serves as a Senior Scientist at the Wyss Institute for Biologically Inspired Engineering working at the 3D Organ Engineering Initiative since 2018 and is leading a Wyss Validation Project aiming to fabricate vascularized functional tissues for transplantation. Her interest is in tissue and organ engineering, focusing on vascularization and implantation studies utilizing complex surgical models. Dr. Perry’s background is in molecular biology, pharmacology, and biomedical engineering, with a Bachelor of Science - BS, Biology, Master of Science - MS, Molecular Pharmacology, and a Doctor of Philosophy - PhD, Biotechnology, all from Technion - Israel Institute of Technology.  She also has industry experience in a vascular gene therapy company (MGVS, now VESSL Therapeutics).#LubaPerry #Harvard #WyssInstitute #ReConstructBio #Aesthetics #3DOrganEngineering #BreastReconstruction #BreastAugmentation #Vascularization #Innervation #Fat #AdiposeTissue #BreastImplants #Organogenesis #OrganEngineering #TissueEngineering #Bioengineering #Organs #Tissues #MolecularPharmacology #Breasts #Nipples#ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast  #STEM #Innovation #Technology #Science #ResearchSupport the show